Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer

Eur J Cancer. 2009 Sep;45(14):2444-6. doi: 10.1016/j.ejca.2009.07.001. Epub 2009 Aug 3.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Anthracyclines / metabolism
  • Anthracyclines / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / metabolism*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Chemotherapy, Adjuvant / methods
  • Cyclophosphamide / administration & dosage
  • Epirubicin / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Methotrexate / administration & dosage
  • Peptide Hydrolases / metabolism
  • Tissue Inhibitor of Metalloproteinase-1 / metabolism*

Substances

  • Anthracyclines
  • Biomarkers, Tumor
  • Tissue Inhibitor of Metalloproteinase-1
  • Epirubicin
  • Cyclophosphamide
  • Peptide Hydrolases
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • CMF regimen
  • FEC protocol